Affymetrix, Inc. (AFFX) Announces Second Quarter 2008 Results and Manufacturing Restructuring to Improve Gross Margins
Affymetrix, Inc. (NASDAQ: AFFX), the developer of products designed to accelerate genetic research and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases, recently announced the company’s operating results for the second quarter of 2008. Total revenue for the quarter came in at $86.9 million, compared to total revenue of $88.3 million during the second quarter of 2007. Shares of Affymetrix, Inc. fell to a multi-year low late last week after the company reported net loss of approximately $3.6 million or $0.05 per diluted share in the second quarter of 2008. Total product…